BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18206228)

  • 1. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia.
    Wagner M; Schmelz K; Dörken B; Tamm I
    Leuk Res; 2008 Jul; 32(7):1054-60. PubMed ID: 18206228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML1/ETO-induced survivin expression inhibits transcriptional regulation of myeloid differentiation.
    Balkhi MY; Christopeit M; Chen Y; Geletu M; Behre G
    Exp Hematol; 2008 Nov; 36(11):1449-60. PubMed ID: 18687517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SSCP detection of N-ras promoter mutations in AML patients.
    Thorn J; Molloy P; Iland H
    Exp Hematol; 1995 Sep; 23(10):1098-103. PubMed ID: 7656930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin promoter polymorphism and cervical carcinogenesis.
    Borbély AA; Murvai M; Szarka K; Kónya J; Gergely L; Hernádi Z; Veress G
    J Clin Pathol; 2007 Mar; 60(3):303-6. PubMed ID: 16714396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias.
    Chim CS; Wong AS; Kwong YL
    Am J Hematol; 2005 Dec; 80(4):282-7. PubMed ID: 16315255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induced epigenetic modifications of the promoter chromatin silence survivin and inhibit tumor growth.
    Ma AN; Huang WL; Wu ZN; Hu JF; Li T; Zhou XJ; Wang YX
    Biochem Biophys Res Commun; 2010 Mar; 393(4):592-7. PubMed ID: 20152814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic changes in therapy-related MDS/AML.
    Voso MT; D'Alò F; Greco M; Fabiani E; Criscuolo M; Migliara G; Pagano L; Fianchi L; Guidi F; Hohaus S; Leone G
    Chem Biol Interact; 2010 Mar; 184(1-2):46-9. PubMed ID: 19874806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma.
    Cheng ZJ; Hu LH; Huang SJ
    Ai Zheng; 2008 Mar; 27(3):258-63. PubMed ID: 18334114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of p300 gene promoter methylation in acute leukemia.
    Chim CS; Wong AS; Kwong YL
    Cancer Genet Cytogenet; 2004 Apr; 150(2):164-7. PubMed ID: 15066326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-specific activation of the survivin promoter and its potential use in gene therapy.
    Chen JS; Liu JC; Shen L; Rau KM; Kuo HP; Li YM; Shi D; Lee YC; Chang KJ; Hung MC
    Cancer Gene Ther; 2004 Nov; 11(11):740-7. PubMed ID: 15359286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter-hypermethylation associated defective expression of E-cadherin in primary non-small cell lung cancer.
    Wang G; Hu X; Lu C; Su C; Luo S; Luo ZW
    Lung Cancer; 2008 Nov; 62(2):162-72. PubMed ID: 18468719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of drug resistance by silencing Survivin gene expression in acute myeloid leukemia cells.
    Wu YH; You Y; Chen ZC; Zou P
    Acta Biochim Pol; 2008; 55(4):673-80. PubMed ID: 19093040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome.
    Badran A; Yoshida A; Wano Y; Mutoh M; Imamura S; Yamashita T; Tsutani H; Inuzuka M; Ueda T
    Int J Oncol; 2003 Jan; 22(1):59-64. PubMed ID: 12469185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia.
    Jost E; Schmid J; Wilop S; Schubert C; Suzuki H; Herman JG; Osieka R; Galm O
    Br J Haematol; 2008 Sep; 142(5):745-53. PubMed ID: 18537968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
    Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
    J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies.
    Flotho C; Paulun A; Batz C; Niemeyer CM
    Br J Haematol; 2007 Sep; 138(5):644-50. PubMed ID: 17686059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of survivin splice variants in pediatric acute precursor B lymphoblastic leukemia.
    Tröger A; Siepermann M; Mahotka C; Wethkamp N; Bülle H; Laws HJ; Escherich G; Janka-Schaub G; Göbel U; Dilloo D
    Klin Padiatr; 2007; 219(3):127-33. PubMed ID: 17525905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia.
    Aggerholm A; Guldberg P; Hokland M; Hokland P
    Cancer Res; 1999 Jan; 59(2):436-41. PubMed ID: 9927059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Terminally differentiated neutrophils predominantly express Survivin-2 alpha, a dominant-negative isoform of survivin.
    Hu H; Shikama Y; Matsuoka I; Kimura J
    J Leukoc Biol; 2008 Feb; 83(2):393-400. PubMed ID: 17965335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.